

Paolo Corradini

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6791150/paolo-corradini-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

305
papers

15,399
citations

69
h-index

116
g-index

323
ext. papers

17,614
ext. citations

5.9
avg, IF

5.61
L-index

#	Paper	IF	Citations
305	Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. <i>ESMO Open</i> , 2022 , 7, 100403	6	4
304	COVID-19 and CAR-T cells: current challenges and future directions-a report from the EPICOVIDEHA survey by EHA-IDWP. <i>Blood Advances</i> , 2021 ,	7.8	3
303	COVID-19 in vaccinated adult patients with hematological malignancies. Preliminary results from EPICOVIDEHA. <i>Blood</i> , 2021 ,	2.2	9
302	Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06. <i>Haematologica</i> , 2021 , 106, 2578-2587	6.6	7
301	CDKN2A deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS). <i>Haematologica</i> , 2021 , 106, 2918-2926	6.6	3
300	A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. <i>Blood Advances</i> , 2021 ,	7.8	4
299	T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies. <i>British Journal of Haematology</i> , 2021 , 196, 548	4.5	13
298	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). <i>Journal of Hematology and Oncology</i> , 2021 , 14, 168	22.4	24
297	A three-gene signature based on , and improves risk stratification in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021 , 106, 2405-2416	6.6	4
296	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021 , 35, 2672-2683	16.3	15
295	Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. <i>Blood Cancer Journal</i> , 2021 , 11, 73	7	3
294	Multicenter Phase II Study on Haploidentical Bone Marrow Transplantation Using a Reduced-Intensity Conditioning Regimen and Posttransplantation Cyclophosphamide in Patients with Poor-Prognosis Lymphomas. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 328.e1-328.e6		
293	Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2021 , 137, 3027-3036	2.2	15
292	Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party-EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 655-663	4.4	1
291	Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 101-107	4.4	0
290	A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL). <i>British Journal of Haematology</i> , 2021 , 193, 280-289	4.5	3
289	Allogeneic Stem-cell Transplantation 2021 , 319-327		

288	Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2606-2609	4.4	1
287	COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. <i>British Journal of Haematology</i> , 2021 , 195, 371-377	4.5	15
286	Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021 , 27, 6479-6490	12.9	1
285	Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial. <i>Blood Cancer Journal</i> , 2021 , 11, 197	7	1
284	Handling the COVID-19 pandemic in the oncological setting. <i>Lancet Haematology</i> , 2020 , 7, e365-e366	4.6	7
283	Nilotinib in steroid-refractory cGVHD: prospective parallel evaluation of response, according to NIH criteria and exploratory response criteria (GITMO criteria). <i>Bone Marrow Transplantation</i> , 2020 , 55, 2077-2086	4.4	3
282	Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy. <i>Hematological Oncology</i> , 2020 , 38, 501-508	1.3	7
281	Timing the initiation of multiple myeloma. <i>Nature Communications</i> , 2020 , 11, 1917	17.4	36
280	Revealing Transcriptome Deregulation upon Genomic Complexity in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 3-4	2.2	
279	Brentuximab Vedotin As Single Agent in the Treatment of Relapsed/Refractory CD30 Positive Peripheral T-Cell Lymphoma Patients: A Phase 2 Study of the Fondazione Italiana Linfomi. <i>Blood</i> , 2020 , 136, 21-21	2.2	0
278	Allogeneic Transplantation for Relapsed Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , 2020 , 365-380		0
277	Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 509-518	2	31
276	Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia. <i>Bone Marrow Transplantation</i> , 2020 , 55, 884-890	4.4	9
275	Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse. <i>British Journal of Haematology</i> , 2020 , 188, 907-917	4.5	3
274	Selective inhibitors of nuclear export in aggressive B-cell lymphomas. <i>Lancet Haematology</i> , 2020 , 7, e500-e501	14.6	1
273	Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. <i>Lancet Haematology</i> , 2020 , 7, e861-e873	14.6	19
272	Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients. <i>BMC Cancer</i> , 2020 , 20, 1140	4.8	4
271	The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PET-2-adapted HD0607 trial. <i>Cancer Medicine</i> , 2020 , 9, 8735-8746	4.8	6

270	Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, e256-e262	4.7	2
269	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. <i>Lancet Haematology</i> , 2020 , 7, e737-e745	14.6	223
268	Limits and Applications of Genomic Analysis of Circulating Tumor DNA as a Liquid Biopsy in Asymptomatic Forms of Multiple Myeloma. <i>HemaSphere</i> , 2020 , 4, e402	0.3	5
267	High Throughput Molecular Characterization of Normal Karyotype Acute Myeloid Leukemia in the Context of the Prospective Trial 02/06 of the Northern Italy Leukemia Group (NILG). <i>Cancers</i> , 2020 , 12,	6.6	2
266	Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 115	22.4	15
265	Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. <i>Haematologica</i> , 2020 , 105, 193-200	6.6	12
264	Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. <i>Blood Advances</i> , 2020 , 4, 830-844	7.8	21
263	Genomic landscape and chronological reconstruction of driver events in multiple myeloma. <i>Nature Communications</i> , 2019 , 10, 3835	17.4	94
262	Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma. <i>British Journal of Cancer</i> , 2019 , 121, 567-577	8.7	2
261	INTRAVENOUS IMMUNOGLOBULIN THERAPY USE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH TISAGENLEUCEL IN THE JULIET TRIAL. <i>Hematological Oncology</i> , 2019 , 37, 505-507	1.3	2
260	Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-III trial. <i>Haematologica</i> , 2019 , 104, 2241-2248	6.6	6
259	Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma. <i>American Journal of Hematology</i> , 2019 , 94, 628-634	7.1	7
258	Ocular disorders in multiple myeloma patients: cross-sectional study of prevalence and association with treatment. <i>Leukemia and Lymphoma</i> , 2019 , 60, 477-482	1.9	3
257	Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT. <i>JAMA Oncology</i> , 2019 , 5, 715-722	13.4	30
256	Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML. <i>Blood Advances</i> , 2019 , 3, 1103-1117	7.8	11
255	PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. <i>Blood Advances</i> , 2019 , 3, 360-369	7.8	59
254	CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL EVENTS IN TISAGENLEUCEL-TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS. <i>Hematological Oncology</i> , 2019 , 37, 308-310	1.3	3
253	Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes?. <i>HemaSphere</i> , 2019 , 3, e284	0.3	7

252	First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi. <i>Blood Cancer Journal</i> , 2019 , 9, 100	7	19
251	Real-life feasibility of salvage allogeneic transplantation in peripheral T-cell lymphomas. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1237-1244	4.4	5
250	Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. <i>Leukemia</i> , 2019 , 33, 1047-1051	10.7	12
249	Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. <i>Cancer</i> , 2019 , 125, 90-98	6.4	11
248	Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma. <i>Digestive and Liver Disease</i> , 2019 , 51, 419-424	3.3	4
247	Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1204-1213	1.9	2
246	Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma: long-term outcomes and graft-versus-host disease-free/relapse-free survival. <i>Leukemia and Lymphoma</i> , 2019 , 60, 101-109	1.9	5
245	Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party. <i>British Journal of Haematology</i> , 2018 , 181, 86-96	4.5	14
244	Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 1357-1366	4.9	6
243	Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT. <i>Bone Marrow Transplantation</i> , 2018 , 53, 255-263	4.4	8
242	Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. <i>Leukemia</i> , 2018 , 32, 979-985	10.7	19
241	Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score. <i>Bone Marrow Transplantation</i> , 2018 , 53, 461-473	4.4	17
240	CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2018 , 53, 1522-1531	4.4	13
239	Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 406-409	4.7	14
238	T-Cell Lymphomas 2018 , 1343-1380		
237	Genomic patterns of progression in smoldering multiple myeloma. <i>Nature Communications</i> , 2018 , 9, 3363	7.4	99
236	Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, 533-540	2	7
235	Romidepsin-CHOEP Plus Intensification with up-Front Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: Final Results of Phase Ib PTCL13 Study of the Fondazione Italiana Linfomi. <i>Blood</i> , 2018 , 132, 2902-2902	2.2	2

234	Carfilzomib, bendamustine, and dexamethasone (KBd) in advanced multiple myeloma: The EMN09-trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 8019-8019	2.2	7
233	Whole Genome Sequencing Reveals Recurrent Structural Driver Events in Peripheral T-Cell Lymphomas Not Otherwise Specified. <i>Blood</i> , 2018 , 132, 4115-4115	2.2	
232	Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. <i>Leukemia</i> , 2018 , 32, 1044-1048	10.7	52
231	Daratumumab plus bortezomib and dexamethasone bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. <i>Haematologica</i> , 2018 , 103, 2079-2087	6.6	167
230	Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNA: A Pilot Study. <i>Journal of Molecular Diagnostics</i> , 2018 , 20, 859-870	5.1	24
229	Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors. <i>Annals of Hematology</i> , 2018 , 97, 1301-1315	3	4
228	Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. <i>Leukemia</i> , 2018 , 32, 2604-2616	10.7	90
227	Bronchial fibroepithelial polyp: a clinico-radiologic, bronchoscopic, histopathological and in-situ hybridisation study of 15 cases of a poorly recognised lesion. <i>Clinical Respiratory Journal</i> , 2017 , 11, 43-48 ¹⁻⁷		8
226	Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis: where do we stand?. <i>Expert Review of Hematology</i> , 2017 , 10, 479-492	2.8	32
225	Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 1102-1109	4.7	5
224	Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 1549-1554	4.7	21
223	New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 821-836	5.4	3
222	Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. <i>European Journal of Haematology</i> , 2017 , 99, 199-206	3.8	15
221	Next-generation sequencing of a family with a high penetrance of monoclonal gammopathies for the identification of candidate risk alleles. <i>Cancer</i> , 2017 , 123, 3701-3708	6.4	8
220	Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2017 , 52, 372-380 ⁴	4.4	35
219	Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma. <i>Leukemia Research</i> , 2017 , 62, 91-97	2.7	14
218	Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3425-3432	2.2	100
217	Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients. <i>Bone Marrow Transplantation</i> , 2017 , 52, 1602-1608	4.4	12

216	ALLOGENEIC TRANSPLANTATION IN HODGKIN'S LYMPHOMA AFTER A FAILED AUTOGRAFT: LONG TERM OUTCOMES AND GRAFT-VERSUS-HOST DISEASE FREE/RELAPSE-FREE SURVIVAL (GRFS). <i>Hematological Oncology</i> , 2017 , 35, 169-190	1.3	
215	FIL-PTCL13: PHASE IB/II STUDY OF ROMIDEPSIN/CHOEP FOLLOWED BY HIGH-DOSE CHEMOTHERAPY AND TRANSPLANTATION IN UNTREATED PERIPHERAL T-CELL LYMPHOMAS.. <i>Hematological Oncology</i> , 2017 , 35, 426-426	1.3	
214	Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma. <i>Haematologica</i> , 2017 , 102, 1931-1935	6.6	7
213	Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogeneic hematopoietic stem cell transplantation for hematological malignancies: two case reports. <i>Haematologica</i> , 2017 , 102, e423-e426	6.6	5
212	Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma. <i>Oncotarget</i> , 2017 , 8, 91703-91710	3.3	12
211	High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression. <i>Blood Cancer Journal</i> , 2016 , 6, e491	7	4
210	Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Annals of Oncology</i> , 2016 , 27, 2251-2257	10.3	31
209	Circulating miRNA panel for prediction of acute graft-versus-host disease in lymphoma patients undergoing matched unrelated hematopoietic stem cell transplantation. <i>Experimental Hematology</i> , 2016 , 44, 624-634.e1	3.1	22
208	Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2370-4	1.9	4
207	Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 94, 783-91	4	30
206	Carfilzomib in Combination with Bendamustine and Dexamethasone (CBd) in Relapsed and/or Refractory Patients with Multiple Myeloma: The Phase I/II EMN09 Study. <i>Blood</i> , 2016 , 128, 3334-3334	2.2	5
205	The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs Era. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016 , 8, e2016045	3.2	2
204	Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper. <i>European Journal of Haematology</i> , 2016 , 97, 554-561	3.8	6
203	Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease: An Italian Multicentric Retrospective Analysis on 94 Patients on Behalf of the Gruppo Italiano Trapianto di Midollo Osseo. <i>Transplantation</i> , 2016 , 100, e147-e155	1.8	30
202	A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients. <i>Journal of Hematology and Oncology</i> , 2016 , 9, 38	22.4	26
201	Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation. <i>Leukemia</i> , 2016 , 30, 2086-2089	10.7	33
200	Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. <i>Blood</i> , 2016 , 128, 497-503	2.2	117
199	Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4015-4022	2.2	49

198	The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1068-73	4.7	36
197	Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers. <i>Oncologist</i> , 2015 , 20, 323-8	5.7	25
196	Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin lymphoma: experience with 27 patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 404-8	2	17
195	Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. <i>Blood</i> , 2015 , 125, 2855-64	2.2	100
194	Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective. <i>European Journal of Haematology</i> , 2015 , 94, 12-22	3.8	14
193	Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 1525-1536	21.7	103
192	Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3459-66	2.2	104
191	Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2015 , 26 Suppl 5, v108-15	10.3	107
190	Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 1617-29	21.7	218
189	Recurrent Hodgkin lymphoma: toward a new definition of candidates for autologous stem cell transplant in the era of positron emission tomography scan and novel agents. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1969-74	1.9	1
188	The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma. <i>Leukemia</i> , 2015 , 29, 464-73	10.7	57
187	Rituximab for indolent lymphomas before and after allogeneic hematopoietic stem cell transplantation. <i>Current Opinion in Hematology</i> , 2015 , 22, 469-75	3.3	
186	Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects. <i>Clinical Cancer Research</i> , 2015 , 21, 3740-9	12.9	80
185	Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 507-13	2	11
184	An uncommon cause of weaning failure from mechanical ventilation. <i>Intensive Care Medicine</i> , 2015 , 41, 327-8	14.5	
183	Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial. <i>Bone Marrow Transplantation</i> , 2015 , 50, 505-10	4.4	13
182	Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients. <i>Blood</i> , 2015 , 126, 3937-3937 ^{2.2}		
181	Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2014 , 164, 258-65	4.5	54

180	Graft monocytic myeloid-derived suppressor cell content predicts the risk of acute graft-versus-host disease after allogeneic transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood stem cells. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 2049-55	4.7	53
179	Serum thymus and activation-regulated chemokine level monitoring may predict disease relapse detected by PET scan after reduced-intensity allogeneic stem cell transplantation in patients with Hodgkin lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1982-8	4.7	12
178	Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. <i>Leukemia</i> , 2014 , 28, 1885-91	10.7	66
177	Autologous transplantation and maintenance therapy in multiple myeloma. <i>New England Journal of Medicine</i> , 2014 , 371, 895-905	59.2	539
176	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncology</i> , 2014 , 15, 1195-206	21.7	604
175	Autologous stem cell transplantation for T-cell lymphomas. <i>Seminars in Hematology</i> , 2014 , 51, 59-66	4	15
174	Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 885-90	4.7	37
173	High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib. <i>Haematologica</i> , 2014 , 99, e14-6	6.6	33
172	Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?. <i>Blood</i> , 2014 , 124, 3841-9	2.2	158
171	Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor. <i>Leukemia and Lymphoma</i> , 2014 , 55, 331-6	1.9	24
170	Plerixafor on demand results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy+G-CSF. <i>Bone Marrow Transplantation</i> , 2014 , 49, 453-5	4.4	8
169	Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2032-7	1.9	21
168	Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases. <i>Clinical Cancer Research</i> , 2014 , 20, 5641-51	12.9	28
167	Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi. <i>British Journal of Haematology</i> , 2014 , 166, 140-2	4.5	27
166	SIE-SIES-GITMO guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias. <i>Annals of Oncology</i> , 2014 , 25, 2339-2350	10.3	14
165	Experts considerations on HLA-haploidentical stem cell transplantation. <i>European Journal of Haematology</i> , 2014 , 93, 187-97	3.8	23
164	Molecular methods for detection of minimal residual disease following transplantation in lymphoid and plasma cell disorders. <i>Methods in Molecular Biology</i> , 2014 , 1109, 209-37	1.4	3
163	Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2013 , 88, 581-8	7.1	46

162	Current state of art for transplantation paradigms in peripheral T-cell lymphomas. <i>Expert Review of Hematology</i> , 2013 , 6, 465-74	2.8	2
161	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <i>Annals of Oncology</i> , 2013 , 24, 561-76	10.3	162
160	Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 424-8	4.7	22
159	Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 940-8	4.7	17
158	A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2013 , 160, 649-59	4.5	94
157	Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. <i>Haematologica</i> , 2013 , 98, 1232-6	6.6	57
156	Successful second autologous engraftment after long duration storage of hematopoietic stem cells. <i>Bone Marrow Transplantation</i> , 2013 , 48, 1480-1	4.4	2
155	Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2013 , 90, 340-4	3.8	2
154	The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo. <i>Leukemia</i> , 2013 , 27, 2086-91	10.7	31
153	Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. <i>Blood</i> , 2013 , 122, 2799-806	2.2	70
152	Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. <i>Blood</i> , 2013 , 121, 5055-63	2.2	153
151	Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. <i>Blood</i> , 2013 , 122, 1376-83	2.2	66
150	Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. <i>Blood</i> , 2013 , 122, 4111-8	2.2	69
149	Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. <i>Haematologica</i> , 2013 , 98, 1014-21	6.6	83
148	High-Dose Rituximab In The Conditioning Regimen Before Allogeneic Stem Cell Transplantation Decreases Deaths Related To Gvhd Without Affecting The Anti-Lymphoma Effect. <i>Blood</i> , 2013 , 122, 2059-2059 ²	3.3	2059 ²
147	Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphomas 2013 , 229-242		
146	Long-term patterns of humoral and cellular response after vaccination against influenza A (H1N1) in patients with hematologic malignancies. <i>European Journal of Haematology</i> , 2012 , 89, 111-9	3.8	11
145	Phase II study of sorafenib in patients with relapsed or refractory lymphoma. <i>British Journal of Haematology</i> , 2012 , 158, 108-19	4.5	33

144	Response-adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression-free survival in transplanted patients with multiple myeloma. <i>American Journal of Hematology</i> , 2012 , 87, 150-4	7.1	8
143	Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. <i>Blood</i> , 2012 , 119, 933-9; quiz 1093	2.2	212
142	Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2012 , 53, 789-95	1.9	12
141	Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 617-26	4.7	65
140	SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. <i>Annals of Hematology</i> , 2012 , 91, 875-88	3	27
139	Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients. <i>Leukemia</i> , 2012 , 26, 1779-85	10.7	13
138	Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. <i>Leukemia</i> , 2012 , 26, 520-6	10.7	101
137	Challenges for the next decade: allogeneic stem cell transplantation in chronic lymphocytic leukemia. <i>Leukemia Supplements</i> , 2012 , 1, S33-4	75	
136	Phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma (PANORAMA 1).. <i>Journal of Clinical Oncology</i> , 2012 , 30, e18572-e18572	2.2	4
135	Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients. <i>European Journal of Cancer</i> , 2011 , 47, 814-8	7.5	14
134	Allogeneic transplantation for Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2011 , 152, 261-72	4.5	20
133	No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. <i>Annals of Oncology</i> , 2011 , 22, 1614-1621	10.3	36
132	Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1262-70	1.9	11
131	Dioxin exposure of human CD34+ hemopoietic cells induces gene expression modulation that recapitulates its in vivo clinical and biological effects. <i>Toxicology</i> , 2011 , 283, 18-23	4.4	10
130	Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3016-22	2.2	149
129	Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. <i>Journal of Clinical Oncology</i> , 2011 , 29, 814-24	2.2	122
128	Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2011 , 96, 937-42	6.6	52
127	Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1,. <i>Blood</i> , 2011 , 118, 3976-3976	2.2	10

126	Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status. <i>Bone Marrow Transplantation</i> , 2010 , 45, 505-12	4.4	12
125	Immune reconstitution inflammatory syndrome associated with <i>Aspergillus terreus</i> pulmonary infection in an autologous stem cell transplant recipient. <i>Transplant Infectious Disease</i> , 2010 , 12, 64-8	2.7	12
124	Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. <i>Journal of Clinical Oncology</i> , 2010 , 28, 800-7	2.2	146
123	High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2227-32	2.2	106
122	Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. <i>Blood</i> , 2010 , 115, 3671-7	2.2	129
121	Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. <i>Lancet Oncology</i> , 2010 , 11, 2071-81	4.0	672
120	Allogeneic transplantation for lymphoma: long-term outcome. <i>Current Opinion in Hematology</i> , 2010 , 17, 522-30	3.3	8
119	Pretransplantation [18-F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation. <i>Cancer</i> , 2010 , 116, 5001-11	6.4	30
118	Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. <i>European Journal of Haematology</i> , 2009 , 82, 93-105	3.8	17
117	Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. <i>Experimental Hematology</i> , 2009 , 37, 791-8	3.1	75
116	The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. <i>Leukemia</i> , 2009 , 23, 1131-8	10.7	93
115	Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting. <i>Bone Marrow Transplantation</i> , 2009 , 44, 237-42	4.4	14
114	Advances in mobilization for the optimization of autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2009 , 50, 1412-21	1.9	43
113	Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. <i>Haematologica</i> , 2009 , 94, 654-62	6.6	53
112	Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. <i>Blood</i> , 2009 , 113, 4771-9	2.2	64
111	Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. <i>Blood</i> , 2009 , 113, 3375-82	2.2	81
110	Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2009 , 114, 5264-70	2.2	309
109	Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. <i>Leukemia and Lymphoma</i> , 2008 , 49, 2156-62	1.9	122

108	Eosinophilic globules in bronchoalveolar lavage fluid of patients with systemic sclerosis-related interstitial lung disease: a diagnostically useful, previously unreported finding in a retrospective and prospective study, including differential diagnosis with other idiopathic and secondary interstitial lung diseases. <i>American Journal of Clinical Pathology</i> , 2008 , 130-927-33	1.9	1
107	Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innovative nei linfomi survey. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3166-75	2.2	58
106	Does the addition of thalidomide to MP or low-intensity SCT improve survival in elderly multiple myeloma patients?. <i>Nature Clinical Practice Oncology</i> , 2008 , 5, 254-5		
105	Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. <i>Blood</i> , 2008 , 111, 4004-13	2.2	200
104	Traumatic neuroma of the bronchi: bronchoscopy and histology of a hitherto unreported lesion. <i>American Journal of Surgical Pathology</i> , 2008 , 32, 640-1	6.7	7
103	The Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) Predicts Survival and Non-Relapse Mortality in Lymphoma and Myeloma Patients Undergoing Reduced-Intensity or Non-Myeloablative Allogeneic Stem Cell Transplantations .. <i>Blood</i> , 2008 , 112, 2144-2144	2.2	1
102	Phase II Trial of Combination of the Histone Deacetylase Inhibitor ITF2357 and Mecllorethamine Demonstrates Clinical Activity and Safety in Heavily Pretreated Patients with Relapsed/Refractory Hodgkin Lymphoma (HL). <i>Blood</i> , 2008 , 112, 2586-2586	2.2	3
101	Long-Term Follow-up of Patients Affected by Relapsed Lymphomas Receiving Reduced-Intensity Conditioning (RIC) Regimen Followed by Allogeneic Stem Cell Transplantation (Allo-SCT): An Update of the Phase II Study of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). <i>Blood</i> , 2008 , 112, 2332-2332	2.2	1
100	RIC Allogeneic Transplantation Improves the Overall and Progression- Free Survival of Hodgkin Lymphoma Patients Relapsing after Autologous Transplantation: A GITMO Retrospective Study Based on Time of HLA Typing and Donor Availability. <i>Blood</i> , 2008 , 112, 460-460	2.2	
99	Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2007 , 92, 418-20	6.6	13
98	Current role of allogeneic stem cell transplantation in follicular lymphoma. <i>Haematologica</i> , 2007 , 92, 580-2	6.6	1
97	Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma. <i>Haematologica</i> , 2007 , 92, 1513-8	6.6	28
96	Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. <i>Leukemia</i> , 2007 , 21, 12-7	10.7	297
95	Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). <i>Leukemia</i> , 2007 , 21, 1002-11	10.7	55
94	Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. <i>Leukemia</i> , 2007 , 21, 2316-23	10.7	124
93	Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma. <i>European Journal of Haematology</i> , 2007 , 78, 330-7	3.8	22
92	Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4459-65	2.2	276
91	Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma. <i>Leukemia and Lymphoma</i> , 2007 , 48, 759-66	1.9	23

90	Hematopoietic stem cell transplantation in peripheral T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2007 , 48, 1496-501	1.9	12
89	IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3. <i>Cancer Research</i> , 2007 , 67, 3269-75	10.1	16
88	Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. <i>Blood</i> , 2007 , 109, 4698-707	2.2	145
87	Bortezomib after allografting in multiple myeloma: association between neurotoxicity and cyclosporine treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 497-9	4.7	4
86	Molecular methods used for the detection of autologous graft contamination in lymphoid disorders. <i>Methods in Molecular Medicine</i> , 2007 , 134, 179-96		1
85	CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice. <i>Experimental Hematology</i> , 2006 , 34, 721-7	3.1	24
84	Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. <i>Blood</i> , 2006 , 107, 3415-6	2.2	70
83	Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer. <i>Bone Marrow Transplantation</i> , 2006 , 37, 311-5	4.4	1
82	Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2006 , 37, 1135-41	4.4	83
81	Engraftment capacity of mesenchymal cells following hematopoietic stem cell transplantation in patients receiving reduced-intensity conditioning regimen. <i>Leukemia</i> , 2006 , 20, 329-35	10.7	36
80	Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. <i>Leukemia</i> , 2006 , 20, 1533-8	10.7	200
79	Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial. <i>Leukemia</i> , 2006 , 20, 1840-7	10.7	17
78	Incidence of Secondary Myelodysplastic Syndrome/Acute Leukemia in 1,266 Lymphoma Patients Following High-Dose Therapy and Autograft: A Study from GITIL (Gruppo Italiano Terapie Innovative nei Linfomi).. <i>Blood</i> , 2006 , 108, 3369-3369	2.2	1
77	Unrelated Donor Hematopoietic Cell Transplantation after Non-Myeloablative Conditioning for Patients with High Risk Multiple Myeloma.. <i>Blood</i> , 2006 , 108, 3158-3158	2.2	1
76	Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2006 , 91, 837-9	6.6	35
75	Immune-mediated attack in relapsed Hodgkin's lymphoma. <i>Lancet, The</i> , 2005 , 365, 1906-8	4.0	12
74	Molecular Modeling of Stereo- and Regioselectivity of Group 4 Heterocenes in the Polymerization of Propene. <i>Macromolecules</i> , 2005 , 38, 3973-3976	5.5	14
73	Use of intrathecal prophylaxis in allogeneic haematopoietic stem cell transplantation for malignant blood diseases: a survey of the European Group for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2005 , 35, 121-4	4.4	19

72	The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. <i>Bone Marrow Transplantation</i> , 2005 , 35, 609-17	4.4	52
71	Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. <i>Leukemia</i> , 2005 , 19, 1029-33	10.7	135
70	Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. <i>Experimental Hematology</i> , 2005 , 33, 920-7	3.1	35
69	Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. <i>Cancer</i> , 2005 , 104, 2099-103	6.4	49
68	Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5334-46	2.2	106
67	Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6690-8	2.2	53
66	Role of stem cell transplantation in myeloma. <i>Hematology</i> , 2005 , 10 Suppl 1, 127-8	2.2	1
65	Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2172-6	2.2	252
64	Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1460-8	2.2	113
63	Do new century catalysts unravel the mechanism of stereocontrol of old Ziegler-Natta catalysts?. <i>Accounts of Chemical Research</i> , 2004 , 37, 231-41	24.3	206
62	Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers. <i>Blood</i> , 2004 , 103, 3287-95	2.2	44
61	Reduced-Intensity Conditioning (RIC) Followed by Allogeneic Transplantation in Relapsed Lymphomas: Evidence for Graft-Versus-Lymphoma Effect in Low and High Grade Histologies, but Not in Hodgkin Disease.. <i>Blood</i> , 2004 , 104, 808-808	2.2	5
60	Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). <i>Haematologica</i> , 2004 , 89, 717-41	6.6	41
59	PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapy. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1398-403	2.2	33
58	Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). <i>Blood</i> , 2003 , 102, 749-55	2.2	172
57	Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. <i>Blood</i> , 2003 , 102, 1927-9	2.2	160
56	Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone. <i>Experimental Hematology</i> , 2003 , 31, 784-8	3.1	12
55	High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors. <i>Bone Marrow Transplantation</i> , 2003 , 31, 767-73	4.4	11

54	Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2003 , 32, 791-3	4.4	7
53	Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. <i>Leukemia</i> , 2003 , 17, 841-8	10.7	165
52	Qualitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after positive selection of CD34+ cells with small- and large-scale Miltenyi cell sorting system. <i>British Journal of Haematology</i> , 2002 , 117, 642-5	4.5	9
51	Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. <i>Blood</i> , 2002 , 99, 75-82	2.2	133
50	Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. <i>Blood</i> , 2002 , 99, 4234-6	2.2	176
49	High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Blood</i> , 2002 , 100, 1559-65	2.2	80
48	Cytomegalovirus infection in cancer patients receiving granulocyte transfusions. <i>Blood</i> , 2002 , 99, 390-1	2.2	10
47	Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer. <i>Annals of Oncology</i> , 2001 , 12, 1693-8	10.3	42
46	High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity. <i>Leukemia</i> , 2001 , 15, 256-63	10.7	23
45	Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. <i>Leukemia</i> , 2001 , 15, 1941-9	10.7	42
44	A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. <i>Experimental Hematology</i> , 2001 , 29, 183-93	3.1	57
43	P1. Immunoablation with t cell depleted autologous peripheral blood stem cell rescue produces complete remission in thrombocytopenic purpura (TTP) recidivant and refractory to standard treatment. <i>Annals of the Rheumatic Diseases</i> , 2001 , 60, 708-716	2.4	78
42	Central nervous system relapse in a patient with mantle cell lymphoma in continuous clinical and molecular remission at six years since autografting. <i>Leukemia and Lymphoma</i> , 2001 , 40, 679-82	1.9	6
41	What do the people think (and know) about informed consent for participation in a medical trial. <i>Archives of Internal Medicine</i> , 2001 , 161, 768-9		6
40	Overweight as an adverse prognostic factor for non-Hodgkin's lymphoma patients receiving high-dose chemotherapy and autograft. <i>Bone Marrow Transplantation</i> , 2000 , 26, 1185-91	4.4	48
39	Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft. <i>Leukemia</i> , 2000 , 14, 740-7	10.7	31
38	Geometry and Stability of Titanium Chloride Species Adsorbed on the (100) and (110) Cuts of the MgCl ₂ Support of the Heterogeneous Ziegler-Natta Catalysts. <i>Macromolecules</i> , 2000 , 33, 8953-8962	5.5	116
37	Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. <i>Journal of Clinical Oncology</i> , 1999 , 17, 208-15	2.2	198

36	Hemopoietic progenitor cell mobilization and harvest following an intensive chemotherapy debulking in indolent lymphoma patients. <i>Stem Cells</i> , 1999 , 17, 55-61	5.8	25
35	Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions. <i>Leukemia</i> , 1999 , 13, 1456-62	10.7	35
34	Clinical relevance of minimal residual disease monitoring in non-Hodgkin $\text{\textcircled{L}}$ lymphomas: a critical reappraisal of molecular strategies. <i>Leukemia</i> , 1999 , 13, 1691-5	10.7	37
33	G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs. <i>Bone Marrow Transplantation</i> , 1998 , 21, 401-7	4.4	45
32	Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 1998 , 22, 449-55	4.4	40
31	Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. <i>Nature Genetics</i> , 1997 , 17, 226-30	36.3	290
30	Molecular Monitoring of Minimal Residual Disease in Follicular and Mantle Cell Non-Hodgkin $\text{\textcircled{L}}$ Lymphomas Treated With High-Dose Chemotherapy and Peripheral Blood Progenitor Cell Autografting. <i>Blood</i> , 1997 , 89, 724-491	2.2	142
29	A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. <i>Leukemia</i> , 1997 , 11, 1793-8	10.7	94
28	Analysis of the immunoglobulin heavy-chain gene rearrangement providing molecular evidence of second lymphoma in a patient in apparent relapse after autotransplantation. <i>Bone Marrow Transplantation</i> , 1997 , 20, 341-3	4.4	5
27	Peripheral blood progenitor cell mobilization in patients with primary refractory lymphoma or at first relapse: comparison with patients at diagnosis and impact on clinical outcome. <i>British Journal of Haematology</i> , 1997 , 99, 41-6	4.5	15
26	Multiple myeloma: reduced plasma cell contamination in peripheral blood progenitor cell collections performed after repeated high-dose chemotherapy courses. <i>British Journal of Haematology</i> , 1997 , 99, 685-91	4.5	16
25	Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. <i>Blood</i> , 1996 , 88, 2228-2235	2.2	178
24	Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma. <i>British Journal of Haematology</i> , 1996 , 94, 376-8	4.5	26
23	Oncogenes in the Pathogenesis of Multiple Myeloma 1996 , 169-172		
22	Elimination of bcl-2-IgH-positive follicular lymphoma cells from blood transplants with high recovery of hematopoietic progenitors by the miltenyi CD34+ cell sorting system. <i>Bone Marrow Transplantation</i> , 1996 , 18, 1117-21	4.4	20
21	High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. <i>Blood</i> , 1995 , 85, 1596-1602	2.2	121
20	Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma.. <i>EMBO Journal</i> , 1995 , 14, 6209-6217	13	225
19	Haematological support of high-dose sequential chemotherapy: clinical evidence for reduction of toxicity and high response rates in poor risk lymphomas. <i>Annals of Oncology</i> , 1995 , 6 Suppl 4, 3-8	10.3	11

18	Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin lymphoma. <i>Blood</i> , 1994 , 83, 1757-1759	280
17	N- and K-ras oncogenes in plasma cell dyscrasias. <i>Leukemia and Lymphoma</i> , 1994 , 15, 17-20	1.9 23
16	Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. <i>Leukemia</i> , 1994 , 8, 758-760	75
15	Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin lymphoma. <i>Blood</i> , 1994 , 83, 1757-1759	9
14	Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. <i>Blood</i> , 1993 , 81, 2708-2713	2.2 105
13	Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas. <i>Journal of Experimental Medicine</i> , 1993 , 178, 1091-6	16.6 97
12	The mutation of N-ras oncogene does not involve myeloid and erythroid lineages in a case of multiple myeloma. <i>British Journal of Haematology</i> , 1993 , 83, 672-3	4.5 3
11	Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. <i>Blood</i> , 1993 , 81, 2708-13	2.2 24
10	Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. <i>Blood</i> , 1993 , 81, 2708-2713	2.2 2
9	Dual rearrangement of immunoglobulin and T-cell receptor gene in a case of T-cell hairy-cell leukemia. <i>European Journal of Haematology</i> , 1991 , 46, 71-6	3.8 5
8	B cell lymphoma-associated chromosomal translocation involves candidate oncogene <i>lyt-10</i> , homologous to NF-kappa B p50. <i>Cell</i> , 1991 , 67, 1075-87	56.2 388
7	Human homologue of Moloney leukemia virus integration-4 locus (MLVI-4), located 20 kilobases 30 of the <i>myc</i> gene, is rearranged in multiple myelomas. <i>Cancer Research</i> , 1990 , 50, 6478-82	10.1 24
6	Philadelphia-positive thrombocythemia with a complex translocation involving chromosomes 9, 15, and 22. <i>Cancer Genetics and Cytogenetics</i> , 1989 , 39, 77-80	3
5	Free calcium concentration in platelets of patients with essential hypertension. <i>American Journal of Nephrology</i> , 1986 , 6 Suppl 1, 54-6	4.6 3
4	New model of the origin of the stereospecificity in the synthesis of syndiotactic polypropylene. <i>Macromolecules</i> , 1985 , 18, 2030-2034	5.5 33
3	Analysis of models for the Ziegler-Natta stereospecific polymerization on the basis of non-bonded interactions at the catalytic site - The Cossee model. <i>European Polymer Journal</i> , 1979 , 15, 1133-1141	5.2 104
2	Genomic landscape and chronological reconstruction of driver events in multiple myeloma	6
1	Peripheral T-cell lymphomas	187-200

